Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Genetix Pharmaceuticals completes $35mm Series B financing

Executive Summary

First-time investors Third Rock Ventures and Genzyme Ventures teamed up with returning backers TVM Capital, Forbion, and Easton Capital for gene delivery firm Genetix Pharmaceuticals' $35mm Series B round. Nick Leschly, a partner from Third Rock, has been named the company's interim president, and a member from Genzyme Ventures joined the board.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies